SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns Medical Dialogues Bureau31 Oct 2019 4:15 AM GMTNovartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings c...
GSK ovarian cancer drug Zejula gets USFDA nod for wider use Medical Dialogues Bureau24 Oct 2019 4:30 AM GMTZejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million pou...
GSK to sell anti-rabies vaccines Rabipur, Encepur to Bavarian Nordic for USD 1.1 billion Medical Dialogues Bureau22 Oct 2019 4:30 AM GMTThe sale of GSK's anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, to the Denmark-based biotechnology fir...
Carcinogen in popular heartburn drug Zantac triggers safety review by European, US regulators Medical Dialogues Bureau14 Sep 2019 3:45 AM GMTValisure said in its report that it found the impurity in both Sanofi SA's branded Zantac as well as generic versions of the drug. But the FDA would no...
Jubilant Life appoints Novartis Syed Kazmi as President, CEO of its new biotech startup Medical Dialogues Bureau11 Sep 2019 3:55 AM GMTDr Syed Kazmi joins from Novartis Pharmaceuticals Corporation where he was Vice President, Global Head of Business Development & Licensing for Onco...
Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer Medical Dialogues Bureau8 Sep 2019 3:55 AM GMTNovartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cel...
Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna Medical Dialogues Bureau8 Sep 2019 3:30 AM GMTThe first two gene therapies to be included in Cigna Corp's program are blindness therapy, Luxturna, and the most expensive drug in the world Novartis'...
Fight for Vildagliptin: Natco goes to court against Novartis Farhat Nasim7 Sep 2019 11:02 AM GMTMumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court...
Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales Medical Dialogues Bureau7 Sep 2019 3:45 AM GMTRoche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for ...
Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm Medical Dialogues Bureau5 Sep 2019 3:45 AM GMTZURICH: Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss ...
Lindsay Goldberg to buy Bilcare Research in a deal worth USD 279-334 million: Report Medical Dialogues Bureau5 Sep 2019 3:30 AM GMTBilcare Research, which employs 1000 staff and has annual sales of 300 million euros, produces plastic packaging used in the pharmaceutical, consumer g...
Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals Medical Dialogues Bureau3 Sep 2019 4:00 AM GMTNovartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of Bio...
